Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Stocks were boosted in May by easing trade tensions, solid corporate earnings and signs the U.S. economy remains resilient ...

A federal judge in D.C. recently ruled in favor of the U.S. Health Resources and Services Administration (“HRSA”), an administrative agency under ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

The Pharma world is seeing a big opportunity in GLP-1s – the new innovative fast emerging drugs for diabetes & obesity. Kiran ...

President Trump’s executive order aims to bring down drug prices while optimizing IP protections, and Congress should pass ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

Rising drug prices in the United States increase out of pocket health care costs, making it difficult to follow prescription ...